The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase II study of osimertinib for patients with radiotherapy-naïve CNS metastasis of non-small cell lung cancer harboring EGFR mutations: The OCEAN study (LOGIK 1603/WJOG 9116L).
 
Kazushige Wakuda
Honoraria - AstraZeneca; Boehringer Ingelheim; Chugai Pharma; Novartis; Ono Pharmaceutical; Taiho Pharmaceutical
 
Hiroyuki Yamaguchi
Honoraria - Boehringer Ingelheim; Bristol-Myers Squibb; Lilly
Research Funding - Boehringer Ingelheim; Lilly; Novartis
 
Hirotsugu Kenmotsu
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Chugai Pharma; Kyowa Hakko Kirin; Lilly; MSD K.K; Novartis; Ono Pharmaceutical; Taiho Pharmaceutical
Research Funding - AstraZeneca/MedImmune (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst)
 
Minoru Fukuda
Honoraria - Chugai Pharma; Daiichi Sankyo; Kiowa Kirin; Lilly; Ono Pharmaceutical; Roche
Research Funding - AstraZeneca; Lilly; MSD
 
Noriyuki Ebi
No Relationships to Disclose
 
Takayuki Suetsugu
No Relationships to Disclose
 
Koji Inonue
No Relationships to Disclose
 
Kentaro Tanaka
Honoraria - Abbvie; AstraZeneca; Bristol-Myers Squibb; Chugai Pharma; Kiowa Kirin; Lilly; MSD; Novartis; Pfizer; Taiho Pharmaceutical
Research Funding - Boehringer Ingelheim; Chugai Pharma; Ono Pharmaceutical
 
Toshihide Yokoyama
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Chugai Pharma; MSD; Ono Pharmaceutical; Taiho Pharmaceutical
 
Keisuke Kirita
Honoraria - AstraZeneca
 
Osamu Hataji
Honoraria - AstraZeneca; Boehringer Ingelheim; Novartis
Research Funding - AstraZeneca; Boehringer Ingelheim; Chugai Pharma; Daiichi Sankyo; GlaxoSmithKline; Novartis
 
Satoru Miura
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Chugai Pharma; Lilly; MSD
Speakers' Bureau - Abbvie; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Chugai Pharma; Kyowa Hakko Kirin; Lilly; MSD; Novartis; Ono Pharmaceutical; Taiho Pharmaceutical
 
Kenji Chibana
No Relationships to Disclose
 
Kenichi Yoshimura
Honoraria - AstraZeneca; Boehringer Ingelheim; Chugai Pharma; Eisai; Lilly; Nihonkayaku; Novartis; Otsuka; Taiho Pharmaceutical; Takeda
Consulting or Advisory Role - BrightPath Biotheraputics; Nippon Shinyaku
 
Kazuhiko Nakagawa
Honoraria - Abbvie; Astellas Pharma; AstraZeneca Japan; Bayer Yakuhin; Bristol-Myers Squibb; CareNet; Chugai Pharma; Daiichi Sankyo; Hisamitsu Pharmaceutical; Kyorin; Kyorin; Lilly; Medical Review Co., Ltd.; Medicus Shuppan Publishers; Medicus Shuppan Publishers; Merck; MSD K.K; NANZANDO Co.,Ltd.; Nichi-iko; Nikkei Business Publications, Inc; Nippon Boehringer Ingelheim; Nippon Kayaku; Novartis; Ono Pharmaceutical; Pfizer; Roche; Taiho Pharmaceutical; Takeda; Thermo Fisher Scientific; YODOSHA; Yomiuri Telecasting Corporation
Consulting or Advisory Role - Kyorin; Lilly; Ono Pharmaceutical; Pfizer; Takeda
Research Funding - A2 Healthcare (Inst); Abbvie (Inst); Astellas Pharma (Inst); AstraZeneca Japan (Inst); Bayer Yakuhin (Inst); Bristol-Myers Squibb (Inst); Chugai Pharma (Inst); CMIC (Inst); Daiichi Sankyo (Inst); Eisai (Inst); EPS Holdings (Inst); EPS International (Inst); ICON Clinical Research (Inst); IQvia (Inst); Kissei Pharmaceutical (Inst); Kyowa Hakko Kirin (Inst); Lilly (Inst); Merck Serono (Inst); MSD K.K (Inst); Nippon Boehringer Ingelheim (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Otsuka (Inst); PAREXEL International Corp. (Inst); Pfizer (Inst); Pfizer (Inst); SymBio Pharmaceuticals (Inst); Syneos Health (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Nobuyuki Yamamoto
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo; Lilly Japan; MSD; Nippon Kayaku; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical; Takeda
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Chugai Pharma; MSD; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical; Takeda; Thermo Fisher Scientific
Speakers' Bureau - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Chugai Pharma; Kyowa Hakko Kirin; Lilly Japan; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Lilly (Inst); Maruho (Inst); MSD (Inst); Nippon Boehringer Ingelheim (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Shionogi (Inst); Taiho Pharmaceutical (Inst); TERUMO (Inst); Toppan Printing Co. (Inst); Tosoh Corporation (Inst); Tsumura & Co. (Inst)
 
Kenji Sugio
No Relationships to Disclose